These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10490666)

  • 1. [Anti-tuberculosis drug consumption as an indicator of the epidemiological situation of tuberculosis in Spain].
    Gutiérrez M; Castilla J; Noguer I; Díaz P; Arias J; Guerra L
    Gac Sanit; 1999; 13(4):275-81. PubMed ID: 10490666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of tuberculosis underreporting in Greece through comparison with anti-tuberculosis drug consumption.
    Lytras T; Spala G; Bonovas S; Panagiotopoulos T
    PLoS One; 2012; 7(11):e50033. PubMed ID: 23185524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of pyrazinamide as an indicator of tuberculosis epidemiology in Castilla-La Mancha].
    Criado-Alvarez JJ; Sanz Cortés J
    Rev Clin Esp; 2004 Jun; 204(6):298-302. PubMed ID: 15171890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of tuberculosis in Galicia, Spain, 1996-2005.
    Cruz-Ferro E; Fernández-Nogueira E
    Int J Tuberc Lung Dis; 2007 Oct; 11(10):1073-9. PubMed ID: 17945063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to antituberculosis drugs in rural South Africa: rates, patterns, risks, and transmission dynamics.
    Wilkinson D; Pillay M; Davies GR; Sturm AW
    Trans R Soc Trop Med Hyg; 1996; 90(6):692-5. PubMed ID: 9015521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoniazid- and streptomycin-resistant miliary tuberculosis complicated by intracranial tuberculoma in a Japanese infant.
    Ishiwada N; Tokunaga O; Nagasawa K; Ichimoto K; Kinoshita K; Hishiki H; Kohno Y
    Tohoku J Exp Med; 2013 Mar; 229(3):221-5. PubMed ID: 23470647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi.
    Harries AD; Nyong'Onya Mbewe L; Salaniponi FM; Nyangulu DS; Veen J; Ringdal T; Nunn P
    Lancet; 1996 Mar; 347(9004):807-9. PubMed ID: 8622340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
    Khan MY; Kinsara AJ; Osoba AO; Wali S; Samman Y; Memish Z
    Int J Antimicrob Agents; 2001 May; 17(5):415-8. PubMed ID: 11337231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis.
    Botha FJ; Sirgel FA; Parkin DP; van de Wal BW; Donald PR; Mitchison DA
    S Afr Med J; 1996 Feb; 86(2):155-8. PubMed ID: 8619142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capture-recapture and anti-tuberculosis drug prescriptions, Balearic Islands, Spain, 2010-2012.
    Gimenez-Duran J; Galmes-Truyols A; Gonzalez-Cortijo T; Portell-Arbona M; Bosch-Isabel C; Vanrell-Berga JM; Nicolau-Riutort A; Cayla JA
    Int J Tuberc Lung Dis; 2018 Jul; 22(7):754-759. PubMed ID: 29914600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between HIV and tuberculosis: technical guide.
    Bull Pan Am Health Organ; 1993; 27(3):297-310. PubMed ID: 8220525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The use of antitubercular drugs in primary care].
    Blázquez Pérez A; Mateos Campos R
    Aten Primaria; 1999 Mar; 23(4):222-6. PubMed ID: 10333607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in the use of antituberculosis drugs in Spain 1993-1998.
    Blázquez A; Arias J; Mateos-Campos R
    Pharmacoepidemiol Drug Saf; 2003; 12(3):227-36. PubMed ID: 12733476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of tuberculosis].
    Ben Amar J; Dhahri B; Aouina H; Azzabi S; Baccar MA; El Gharbi L; Bouacha H
    Rev Pneumol Clin; 2015; 71(2-3):122-9. PubMed ID: 25434510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.